Olema Pharmaceuticals, Inc. (OLMA)
| Market Cap | 601.11M -18.5% |
| Revenue (ttm) | n/a |
| Net Income | -204.57M |
| EPS | -2.13 |
| Shares Out | 87.50M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,088,435 |
| Open | 6.84 |
| Previous Close | 6.80 |
| Day's Range | 6.70 - 6.95 |
| 52-Week Range | 6.61 - 36.26 |
| Beta | 2.01 |
| Analysts | Strong Buy |
| Price Target | 36.50 (+431.3%) |
| Est. Earnings | Nov 9, 2026 |
About OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in seco... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for OLMA stock is "Strong Buy." The 12-month stock price target is $36.5, which is an increase of 431.30% from the latest price.
News
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developme...
Olema Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Palazestrant is advancing in two phase III trials for ER+, HER2- breast cancer, targeting both ESR1 mutant and wild-type populations, with a key readout expected in Q1 2027. OP-3136, a KAT6 inhibitor, is progressing in breast and prostate cancer, with new combination data anticipated next year.
Olema Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Palazestrant stands out among oral SERDs due to its complete antagonism, high exposure, and unique combinability, with phase III trials targeting both mutant and wild type ESR1 populations. The KAT6 inhibitor pipeline expands opportunities in breast and prostate cancer, supported by strong financials and multiple upcoming catalysts.
Olema Oncology price target lowered to $30 from $48 at Stifel
Stifel lowered the firm’s price target on Olema Oncology (OLMA) to $30 from $48 and keeps a Buy rating on the shares after AstraZeneca (AZN) announced on Friday that its…
Olema selloff on Astra miss ‘significant overreaction,’ says JPMorgan
JPMorgan analyst Anupam Rama keeps an Overweight rating on Olema Oncology (OLMA) after AstraZeneca (AZN) announced that the SERENA-4 study in patients with ER+/HER2- advanced breast cancer missed stat...
Olema selloff on AstraZeneca miss a buying opportunity, says Citi
Citi views the pullback in Olema Oncology (OLMA) after AstraZeneca (AZN) announced the camizestrant plus palbociclib combination did not meet the primary endpoint as a buying opportunity. Astra’s SERE...
Olema Pharmaceuticals Transcript: Citigroup’s Biopharma Back to School Summit 2026
Palazestrant is advancing in two phase III breast cancer trials, targeting both ESR1 mutant and wild-type populations, with top-line data for OPERA-01 expected in Q1 2027 and significant commercial potential. Additional pipeline assets, including a KAT6 inhibitor, are progressing in breast and prostate cancer, while AI is streamlining operations.
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developme...
Olema Oncology price target lowered to $46 from $52 at JPMorgan
JPMorgan lowered the firm’s price target on Olema Oncology (OLMA) to $46 from $52 and keeps an Overweight rating on the shares.
Olema Oncology appoints Jason O’Byrne as CFO
Olema (OLMA) announced the appointment of Jason O’Byrne as CFO. O’Byrne brings more than two decades of finance and global operations leadership across high-growth biotechnology and pharmaceutical org...
Olema Oncology price target lowered to $20 from $23 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Olema Oncology (OLMA) to $20 from $23 and keeps a Buy rating on the shares. Olema’s Q2 update extended its cash runway…
Olema Oncology price target lowered to $59 from $62 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Olema Oncology (OLMA) to $59 from $62 and keeps a Buy rating on the shares.
Olema Oncology price target lowered to $36 from $38 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Olema Oncology (OLMA) to $36 from $38 and keeps a Buy rating on the shares post the Q2 report. OPERA-01 topline data…
Olema Pharmaceuticals Earnings release: Q2 2026
Olema Pharmaceuticals released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Olema Pharmaceuticals Quarterly report: Q2 2026
Olema Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 10, 2026.
Olema Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing two late-stage assets for ER+, HER2- breast cancer, with OPERA-01 phase III data expected in the fall and KAT6 combination data anticipated by year-end. Strong cash reserves support ongoing trials and potential commercialization, while trial designs are being refined based on recent industry data.
Olema Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
OP-3136 and palazestrant clinical programs are advancing, with promising efficacy and safety data in breast and prostate cancer. Upcoming trial readouts and industry data may drive design changes and strategic decisions, while strong cash reserves support ongoing development.
Olema Pharmaceuticals Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
OP-3136, a selective KAT6/KAT7 inhibitor, shows early efficacy and favorable tolerability in phase I, with ongoing and planned combination trials in breast and prostate cancer. Major phase III readouts are expected in the fall, targeting large market opportunities.
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
Study to evaluate OP-3136, Olema's novel KAT6 inhibitor, in combination with darolutamide in approximately 36 patients; expected to initiate in H2 2026 First clinical collaboration for OP-3136; result...
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
OP-3136 monotherapy was well-tolerated with no dose-limiting toxicities observed and no discontinuations due to treatment-related adverse events OP-3136 shows evidence of anti-tumor activity across mu...
Citi opens ‘upside 90-day catalyst watch’ on Olema Oncology
Citi opened an “upside 90-day catalyst watch” on Olema Oncology (OLMA) while keeping a Buy rating on the shares with a $62 price target The company will present initial clinical…
Olema Oncology price target lowered to $35 from $38 at Guggenheim
Guggenheim lowered the firm’s price target on Olema Oncology (OLMA) to $35 from $38 and keeps a Buy rating on the shares. The firm, which has updated its model for…
Olema Pharmaceuticals Quarterly report: Q1 2026
Olema Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 12, 2026.
Olema Pharmaceuticals Earnings release: Q1 2026
Olema Pharmaceuticals released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
SAN FRANCISCO, April 29, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developm...